Targeting dopaminergic system for treating nicotine dependence
| Author | Abuhamdah, Sawsan |
| Author | Khalil, Ashraf |
| Author | Sari, Youssef |
| Available date | 2021-09-01T10:02:40Z |
| Publication Date | 2016 |
| Publication Name | Central Nervous System Agents in Medicinal Chemistry |
| Resource | Scopus |
| Abstract | Background: Smoking is the world's leading cause of preventable death among populations. Cigarette smoking increases the risk of numerous health problems, including heart diseases, stroke, atherosclerosis and many types of cancer, including lung, stomach and bladder cancers. Outcomes: Many individuals find it difficult to stop smoking because of the addictive effects of nicotine and the presence of several monoamine oxidase (MAO) inhibitors in the tobacco smoke extract. Objective: The development of novel, safe and effective medications for smoking cessation is a high public health priority. Results: The role of mesocorticolimbic dopaminergic pathways in withdrawal symptoms and general reinforcement processes clearly recommends dopaminergic system as a potential target for the treatment of nicotine addiction. Conclusion: This review article discusses the new pharmacological treatments of nicotine dependence, which are targeting dopaminergic neurotransmission. This includes blockade of dopamine transporter and inhibition of MAO as pharmacotherapy for the treatment of nicotine dependence. 2016 Bentham Science Publishers. |
| Language | en |
| Publisher | Bentham Science Publishers B.V. |
| Subject | 2 naphthylamine amfebutamone beta carboline dopamine dopamine receptor dopamine transporter farnesol gsk 598809 harman monoamine oxidase A inhibitor monoamine oxidase B inhibitor monoamine oxidase inhibitor n [4 [2 (6 cyano 1,2,3,4 tetrahydro 2 isoquinolinyl)ethyl]cyclohexyl] 4 quinolinecarboxamide nicotine noradrenalin presynaptic receptor serotonin dopamine dopamine receptor blocking agent dopamine transporter monoamine oxidase inhibitor Article dopamine release dopamine uptake dopaminergic nerve cell dopaminergic system drug dependence drug targeting GABAergic system glutamatergic synapse human microdialysis neurotransmission nicotine replacement therapy positron emission tomography prefrontal cortex public health risk factor smoking cessation smoking habit tobacco tobacco dependence ventral tegmentum withdrawal syndrome animal antagonists and inhibitors drug delivery system metabolism procedures Tobacco Use Disorder treatment outcome Animals Dopamine Dopamine Antagonists Dopamine Plasma Membrane Transport Proteins Drug Delivery Systems Humans Monoamine Oxidase Inhibitors Smoking Cessation Tobacco Use Disorder Treatment Outcome |
| Type | Article |
| Pagination | 137-142 |
| Issue Number | 2 |
| Volume Number | 16 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Pharmacy Research [1311 items ]
Related items
Showing items related by title, author, creator and subject.
-
Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors
( Elsevier Masson SAS , 2016 , Article)A novel series of substituted chalcones were designed and synthesized to be evaluated as selective human MAO-B inhibitors. A combination of either methylsulfonyl or trifluoromethyl substituents on the aromatic ketone moiety ... -
Monoamine oxidase inhibitors extracted from tobacco smoke as neuroprotective factors for potential treatment of Parkinson’s disease
( Bentham Science Publishers B.V. , 2015 , Article)Parkinson’s disease (PD) is a neurodegenerative disease characterized by the loss of mainly the nigrostriatal dopaminergic neurons, which leads to motor dysfunction. Although, most of the drugs are currently used for ... -
SAR and molecular mechanism studies of monoamine oxidase inhibition by selected chalcone analogs
( Taylor and Francis Ltd. , 2019 , Article)The present study describes the synthesis of a series of 22 chalcone analogs. These compounds were evaluated as potential human MAO-A and MAO-B inhibitors. The compounds showed varied selectivity against the two isoforms. ...
